Pfizer Ventures

Pfizer Ventures Pfizer Ventures was founded in 2004 as the strategic CVC arm of Pfizer, managing roughly $600M in AUM. Over 20 years, the firm has made 220 total investments, averaging 3 new deals annually, with 72 companies invested and 17 portfolio companies acquired. The notable recent exit was Morphic Therapeutic, acquired by Eli Lilly for $3.2B in July 2024. The latest investment was Mission Therapeutics' Series E-II in October 2025. Investment velocity is moderate. 2 investments in 2024.